GlassScriptPhysician profile
Matthew M Malan
NPI 1861489106
$4,491.62
in general payments reported to CMS, 2019-2025
25 companies · $1,289 in 2025
The $1,289 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,139 · 2024: $2,064 · 2025: $1,289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,305 · Education: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,305.23 |
| Education | $186.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,019.51 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $482.97 | 2023-2024 | Sotyktu |
| Lilly USA, LLC | $382.95 | 2023-2024 | Olumiant, Taltz, Ebglyss |
| Arcutis Biotherapeutics, INC. | $364.90 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $306.51 | 2023-2025 | Dupixent |
| Dermavant Sciences, INC. | $282.74 | 2023-2024 | Vtama |
| Janssen Biotech, INC. | $277.09 | 2023-2025 | Tremfya |
| Galderma Laboratories, L.P. | $211.92 | 2023-2025 | Aklief, Oracea, Twyneo |
| Incyte Corporation | $178.76 | 2023-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $153.58 | 2023-2025 | |
| Genzyme Corporation | $143.82 | 2023-2025 | |
| Leo Pharma INC. | $126.67 | 2024-2025 | Adbry |
| Ucb, INC. | $105.86 | 2024-2025 | Bimzelx |
| Amgen INC. | $69.38 | 2023-2025 | Otezla, Otezla |
| Pfizer INC. | $57.59 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $57.04 | 2024-2025 | |
| Organon LLC | $50.06 | 2025 | Nexplanon, Vtama |
| Botanix Sb INC | $36.42 | 2025 | Sofdra |
| Journey Medical Corporation | $35.32 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.17 | 2025 | |
| Fidia Pharma USA INC. | $31.01 | 2025 | |
| Krystal Biotech INC | $26.03 | 2024 | Vyjuvek |
| Almirall LLC | $23.23 | 2023 | Seysara |
| Organogenesis INC. | $19.64 | 2025 | Via Matrix |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.45 | 2023 | Jublia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Malan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.